INTT News & Events

Latest data shows the largest indicative borrow rate increases among liquid option names include: Xanadu Quantum Technologies Limited Class B (XNDU) 108.67% +13.18, YIELDMAX MSTR OPTION INCOME STRATEGY ETF (MSTY) 11.79% +2.98, Grace Therapeutics, Inc (GRCE) 4.90% +1.63, Tradr 2X Long QBTS Daily ETF (QBTX) 18.40% +1.61, Direxion S&P Biotech Bear 3X (LABD) 15.74% +1.36, Kodiak AI, Inc. Common Stock (KDK) 31.81% +1.21, Anheuser Busch (BUD) 2.34% +1.07, GraniteShares 2x Long IONQ Daily ETF (IONL) 27.15% +0.91, Grupo Financiero (GGAL) 1.36% +0.59, and inTest (INTT) 3.91% +0.50.

Sees FY26 gross margin of approximately 45% and operating expenses of $55M-$57M. Sees FY26 amortization expense $2.6M and interest expense of $300,000. The effective tax rate for the year is expected to be approximately 18%. Capital expenditures are estimated to be approximately 1% to 2% of revenue.

Reports Q1 revenue $33.89M, consensus $31.69M. "InTest delivered a good start to 2026, with first quarter results slightly ahead of guidance, reflecting our strong execution," stated Rich Rogoff, President and CEO. "With 69% of revenue generated from non-semiconductor end markets, we saw strong year-over-year growth across Defense/Aerospace, Life Sciences, and Auto/EV. Our Semi business improved, benefitting from shipments from our backlog1 rather than first quarter orders. These results demonstrate the adoption of new products developed by our engineering teams and the deepening of customer relationships driven by our sales teams."